BRCA1 and breast cancer: Thus, by evaluating HRD scores in this cohort, the GISMG positivity cutoff was predefined with a 95% sensitivity for detecting tumors with BRCA1/2* or BRCA-CpG+; this test was then evaluated for its ability to identify Pt-S triple-negative BC (TNBC) in a neoadjuvant setting [132].